Fertilizers: 3QCY25 Preview – Payout up, profit down 12% YoY











Pakistan 2022



Most Innovative Corporate Finance Advisory Firm - Pakistan 2022 Fastest Growing Asset Manager -Pakistan 2022



Best Brokerage House 2017 Best Brokerage House 2016 (Runner-up) Best Analyst & Trader 2013 (Runner-up)



Sector Coverage of Bank, Insurance, Power, Macroeconomics, Small Caps, Materials Runner Up

3QCY25 earnings down by **12%** YoY



Fertilizer earnings to decrease by 12% YoY

We estimate that the earnings of the BMA Fertilizer universe will decline by 12% YoY to PkR 29.2bn in 3QCY25. This decrease is primarily driven by a 45% YoY drop in other income, a 7% YoY decline in urea prices, and a 19% YoY fall in DAP volumes. On a QoQ basis, earnings are also expected to fall by 5%, mainly due to lower other income and a reduction in urea prices.

Better Urea off-take

Urea sales are projected to increase by 21% YoY and 48% QoQ to 1.8mn tons in 3QCY25, while DAP off-take is expected to decline by 19% YoY and up 3% QoQ, reaching 314k tons during the same period. Urea sales increased due to aggressive manufacturer discounting and dealer pre-buying, in our view.

7% YoY decline in urea price while DAP price up by 15% YoY

During 3QCY25, the average urea price reduced by 7% YoY to PkR 4,404 per bag due to discounts offered the by the Engro Fertilizer Limited (EFERT) and Fauji Fertilizer Company Limited (FFC) to reduce inventory levels. However, DAP prices increased by 15% YoY to PkR 13,449 per bag.

Fauji Fertilizer Company (FFC)

We anticipate FFC to report an unconsolidated EPS of PkR 15.8 in 3QCY25, reflecting a 8% YoY and 11% QoQ decline. This decline is driven by two key factors: (1) lower other income, and (2) lower gross margin. Additionally, we expect the company to announce a cash dividend of PkR 12 per share alongside the results.

Engro Fertilizers (EFERT)

We project EFERT's consolidated EPS to reach PkR 5.1 in 3QCY25, reflecting a 21% YoY decrease compared to PkR 6.4 in 3QCY24. This YoY decline is attributed to lower DAP sales, lower urea price and higher finance cost. However, on QoQ earnings are expected to increase by 22% QoQ, driven by a 37% QoQ increase in urea off-take and a 7% QoQ surge in DAP price. Additionally, we expect the company to announce a cash dividend of PkR 5.0 per share alongside the results.

Pakistan Fertilizer Earnings Estimates						
PkR	3QCY25E	3QCY24A	YoY	2QCY25A	QoQ	
FFC	15.8	17.2	-8%	17.7	-11%	
EFERT*	5.1	6.4	-21%	4.2	22%	

Source: Company Accounts, BMA Research, *Consolidated

Pakistan Urea Expected Off-take in 3QCY25					
K Tons	3QCY25E	3QCY24A	YoY	2QCY25A	QoQ
FFC	832	729	14%	585	42%
EFERT	589	466	26%	431	37%
Others	432	341	27%	235	84%
Total	1,853	1,536	21%	1,251	48%

Source: NDFC, BMA Research

Pakistan DAP Expected Off-take in 3QCY25					
K Tons	2QCY25E	2QCY24A	YoY	1QCY25A	QoQ
FFC	253	229	11%	67	278%
EFERT	14	70	-81%	56	-76%
Others	48	87	-45%	182	-74%
Total	314	386	-19%	305	3%

Source: NDFC, BMA Research

Urea & DAP Prices in 3QCY25					
PkR/Bag	3QCY25A	3QCY24A	YoY	2QCY25A	QoQ
Urea	4,404	4,718	-7%	4,476	-2%
DAP	13,449	11,657	15%	12,579	7%

Source: NDFC, BMA Research

Fahad Hussain Khan

Deputy Head of Research

BMA Capital Management Ltd.

E-mail: fahad.hussain@bmacapital.com

Disclaimer



This research report is for information purposes only and does not constitute nor is it intended as an offer or solicitation for the purchase or sale of securities or other financial instruments. Neither the information contained in this research report, nor any future information made available with the subject matter contained herein will form the basis of any contract. Information and opinions contained herein have been compiled or arrived at by BMA Capital Management Limited from publicly available information and sources that BMA Capital Management Limited believed to be reliable. Whilst every care has been taken in preparing this research report, no research analyst, director, officer, employee, agent or adviser of any member of BMA Capital Management Limited gives or makes any representation, warranty or undertaking, whether express or implied, and accepts no responsibility or liability as to the reliability, accuracy or completeness of the information set out in this research report. Any responsibility or liability for any information contained herein is expressly disclaimed. All information contained herein is subject to change at any time without notice. No member of BMA Capital Management Limited has an obligation to update, modify or amend this research report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. Furthermore, past performance is not indicative of future results.

The investments and strategies discussed herein may not be suitable for all investors or any particular class of investor. Investors should make their own investment decisions using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives when investing. Investors should consult their independent advisors if they have any doubts as to the applicability to their business or investment objectives of the information and the strategies discussed herein. This research report is being furnished to certain persons as permitted by applicable law, and accordingly may not be reproduced or circulated to any other person without the prior written consent of a member of BMA Capital Management Limited. This research report may not be relied upon by any retail customers or person to whom this research report may not be provided by law. Unauthorized use or disclosure of this research report is strictly prohibited. Members of BMA Capital Management and/or their respective principals, directors, officers and employees may own, have positions or effect transactions in the securities or financial instruments referred herein or in the investments of any issuers discussed herein, may engage in securities transactions in a manner inconsistent with the research contained in this research report, and with respect to securities or financial instruments covered by this research report, may sell to or buy from customers on a principal basis and may serve or act as director, placement agent, advisor or lender, or make a market in, or may have been a manager or a co-manager of the most recent public offering in respect of any investments or issuers of such securities or financial instruments referenced in this research report or may perform any other investment banking or other services for, or solicit investment banking or other business from any company mentioned in this research report. Investing in Pakistan involves a high degree of risk and many persons, physi

BMA Capital Management Limited and / or any of its affiliates, which operate outside Pakistan, do and seek to do business with the company(s) covered in this research document. Investors should consider this research report as only a single factor in making their investment decision. BMA Research Policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer/company prior to the publication of a research report containing such rating, recommendation or investment thesis.

Stock Rating

Investors should carefully read the definitions of all rating used within every research reports. In addition, research reports carry an analyst's independent view and investors should ensure careful reading of the entire research reports and not infer its contents from the rating ascribed by the analyst. Ratings should not be used or relied upon as investment advice. An investor's decision to buy, hold or sell a stock should depend on said individual's circumstances and other considerations. BMA Capital Limited uses a three-tier rating system: i) Buy, ii) Neutral and iii) Underperform (new rating system effective Jan 1'18) with our rating being based on total stock returns versus BMA's index target return for the year. A table presenting BMA's rating definitions is given below:

Old rating system

Valuation Methodology

To arrive at our period end target prices, BMA Capital uses different valuation methodologies including

- Discounted cash flow (DCF, DDM)
- Relative Valuation (P/E, P/B, P/S etc.)
- Equity & Asset return based methodologies (EVA, Residual Income etc.)

BMA Branches



BMA CAPITAL MANAGEMENT LIMITED TREC HOLDER AT PAKISTAN STOCK EXCHANGE LIMITED

HEAD OFFICE:

Level 8, Unitower, I.I. Chundrigar Road, Karachi - 74000, Pakistan
Tel: +92 21 111 262 111 | Fax: +92 21 3243 0748 | www.bmacapital.com | info@bmacapital.com

Stock Exchange Branch:

Room 141, Pakistan Stock Exchange, Stock Exchange Road, Karachi. Tel: (021) 32410617

Awami Markaz Branch:

G13, Ground floor, Awami Markaz, Shahrah-e-Faisal Karachi. Tel: (021) 34300578

Islamabad Branch:

104, 1st Floor, 82–East, Muhammad Gulistan Khan House, Fazel e Haq, Blue Area, Islamabad Pakistan

Tel: (051) 280 2354-5 Fax: (051) 280 2356

Faisalabad Branch:

Mezzanine Floor, State Life Building #2, Plot No. 833 Liaquat Road, Faisalabad. Tel: (041) 2612261-5.

Peshawar Branch:

Shop No.F1 & F2, 1st Floor Mall Tower 35,

The Mall Peshawar Cantt. Tel: (091) 5274770-72

Bahadurabad Branch:

Office # 3, Mezzanine Floor, Akber Manzil, Main Bahadurabad Roundabout, Karachi Tel: (021) 3486 0393-98 Fax: (021) 3493 1396

Lahore Cavalry Branch:

Office No. 74, 2nd Floor, Commercial Area, Main Cavalry Ground, Lahore Cantt, Lahore.

Tel: (042) 3667 6614-20 Fax: (042) 3661 9912

Sialkot Branch:

2nd Floor, Sialkot Business & Commerce Centre, Paris Road, Sialkot, Adjacent to Sialkot Chamber of Commerce.
Tel: (052) 4260091-94

Gujranwala Branch:

51-H block Near Standard Chartered Bank Trust Plaza GT road Gujranwala. Tel: (055) 3848501-05

Abbottabad Branch:

Gohar Son's Arcade 1st Floor Office# 4, Supply Bazar Sikandarabad Abbottabad, KPK. Tel: (0992) 400346-47

Gulshan-e-Iqbal Branch:

Commercial Office premises bearing, B-29 Mezzanine Floor 13/A, Main University Road, Gulshan-e-Iqbal Karachi.

Tel: (021) 34825023

Lahore Gulberg Branch:

Commercial Office No. 402, 7th Floor, Mega Tower 63–B, Main Boulevard, Gulberg II, Lahore. Tel: (042) 35762953–57

Multan Branch:

Office No. 607/A, 6th Floor, The United Mall, Plot No. 74 Abdali Road, Multan Tel: (061) 457 6611-15 Fax: (061) 457 6615

Chakwal Branch:

Office No. 12, 1st Floor, Ejaz Plaza, Talagang Road Chakwal. Tel: (0543) 553850, 0543–543720,0543–543721.

Gujar Khan Branch:

1st Floor, Office# 101 & 102, Akbar Kayani Plaza, GT Road, Gujar Khan. Tel: (051) 3762083

North Nazimabad Branch:

D-14 Office No 02, 2nd Floor Block H, MCB Building, Near 5 Star Round About, North Nazimabad Karachi. Tel: (021) 36672301-00.

Lahore LSE Branch:

1st Floor Room# 110-111, LSE Building, 19- Khayaban-e-Aiwan-e-Iqbal, Lahore. Tel: (042) 36280931-34

Sargodha Branch:

Ground floor, Shan Plaza, Block No 16, Main Khushab Road, Near Allied Bank Limited, Sargodha. Tel: (048) 3767 817-18

Ihelum:

2nd Floor, Khalid Plaza, Plot#7/89, Kazim Kamal Road, Jhelum, Punjab. Tel: (054) 4620594-97

Bahawalpur Branch:

Plot # 13-A, 1st Floor, Office # 2, Model Town B, Bahawalpur Tel: (062) 2883158, 2884158